Advertisement
Australia markets open in 7 hours 54 minutes
  • ALL ORDS

    8,214.80
    +27.10 (+0.33%)
     
  • AUD/USD

    0.6674
    -0.0069 (-1.02%)
     
  • ASX 200

    8,013.40
    +31.00 (+0.39%)
     
  • OIL

    68.16
    -0.99 (-1.43%)
     
  • GOLD

    2,526.80
    -16.30 (-0.64%)
     
  • Bitcoin AUD

    80,675.48
    -1,482.70 (-1.80%)
     
  • XRP AUD

    0.78
    -0.01 (-1.71%)
     

Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024

Opthea Limited
Opthea Limited

MELBOURNE, Australia and PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference and participate in one-on-one investor meetings on August 15, 2024.

Virtual Conference Details:

Presentation: Available on Thursday, August 15, 2024, 7:00 am ET

Presenter: Frederic Guerard, PharmD, CEO Opthea

The webcast will be accessible both via the link: https://journey.ct.events/view/bc8c5e95-651e-4824-bee8-923a1a7479fa and on the “Events & Presentations” section of Opthea’s website at http://ir.opthea.com/.

About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents.

To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.

Authorized for release to ASX by Frederic Guerard, CEO

Investor Inquiries

PJ Kelleher 
LifeSci Advisors, LLC 
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579

Media Inquiries

Silvana Guerci-Lena 
NorthStream Global Partners 
Email: silvana@nsgpllc.com

Join our email database to receive program updates:  
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com

Source: Opthea Limited